$IMNM
Immunome Inc.

2023 Q1 Form 10-K Financial Statement

#000155837023003964 Filed on March 16, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $2.364M $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.963M $3.574M $13.79M
YoY Change -17.14% 3.32% 24.32%
% of Gross Profit
Research & Development $3.913M $4.213M $23.27M
YoY Change -51.56% -3.92% 64.93%
% of Gross Profit
Depreciation & Amortization $94.00K $95.00K $400.0K
YoY Change -15.32% -19.49% -50.0%
% of Gross Profit
Operating Expenses $6.835M $7.787M $36.90M
YoY Change -41.35% -0.73% 46.41%
Operating Profit -$4.471M -$36.90M
YoY Change -61.64% 46.41%
Interest Expense $201.0K $1.000K $5.000K
YoY Change 20000.0% -120.0% -150.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $5.000K
YoY Change -100.0% -98.99%
Pretax Income -$4.270M -$7.786M -$36.90M
YoY Change -63.36% -0.84% 49.31%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$4.300M -$7.786M -$36.90M
YoY Change -63.25% -0.84% 49.39%
Net Earnings / Revenue -181.9%
Basic Earnings Per Share -$0.35 -$3.09
Diluted Earnings Per Share -$0.35 -$0.64 -$3.09
COMMON SHARES
Basic Shares Outstanding 12.22M 12.13M 12.13M
Diluted Shares Outstanding 12.18M 12.13M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $44.42M $20.32M $20.32M
YoY Change 3.6% -58.72% -58.72%
Cash & Equivalents $44.42M $20.32M
Short-Term Investments
Other Short-Term Assets $1.291M $2.326M $1.479M
YoY Change -50.89% -68.61% -80.04%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $46.54M $22.65M $22.65M
YoY Change 0.5% -60.01% -60.01%
LONG-TERM ASSETS
Property, Plant & Equipment $916.0K $681.0K $965.0K
YoY Change 21.65% -20.35% 12.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $432.0K $432.0K $432.0K
YoY Change -10.37% 0.0% 0.0%
Total Long-Term Assets $1.578M $1.397M $1.397M
YoY Change 10.74% 8.55% 8.55%
TOTAL ASSETS
Total Short-Term Assets $46.54M $22.65M $22.65M
Total Long-Term Assets $1.578M $1.397M $1.397M
Total Assets $48.11M $24.05M $24.05M
YoY Change 0.81% -58.49% -58.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.310M $2.400M $2.400M
YoY Change -14.91% -22.0% -22.0%
Accrued Expenses $3.306M $4.931M $4.931M
YoY Change -43.17% -25.86% -25.86%
Deferred Revenue $18.22M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $24.83M $7.331M $7.331M
YoY Change 155.81% -24.64% -24.64%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $9.421M $62.00K $62.00K
YoY Change 6308.84% 416.67% 416.67%
Total Long-Term Liabilities $9.421M $62.00K $62.00K
YoY Change 6308.84% 416.67% 416.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.83M $7.331M $7.331M
Total Long-Term Liabilities $9.421M $62.00K $62.00K
Total Liabilities $34.25M $7.393M $7.393M
YoY Change 247.59% -24.1% -24.1%
SHAREHOLDERS EQUITY
Retained Earnings -$120.3M -$116.0M
YoY Change 32.49% 46.64%
Common Stock $1.000K $1.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.86M $16.65M $16.65M
YoY Change
Total Liabilities & Shareholders Equity $48.11M $24.05M $24.05M
YoY Change 0.81% -58.49% -58.49%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$4.300M -$7.786M -$36.90M
YoY Change -63.25% -0.84% 49.39%
Depreciation, Depletion And Amortization $94.00K $95.00K $400.0K
YoY Change -15.32% -19.49% -50.0%
Cash From Operating Activities $24.17M -$6.683M -$28.69M
YoY Change -479.12% -1.79% 57.41%
INVESTING ACTIVITIES
Capital Expenditures $106.0K $72.00K $248.0K
YoY Change 1666.67% -614.29% 213.92%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$106.0K -$72.00K -$248.0K
YoY Change 1666.67% 414.29% 213.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 34.00K 0.000 32.00K
YoY Change 6.25% -100.0% -99.88%
NET CHANGE
Cash From Operating Activities 24.17M -6.683M -28.69M
Cash From Investing Activities -106.0K -72.00K -248.0K
Cash From Financing Activities 34.00K 0.000 32.00K
Net Change In Cash 24.10M -6.755M -28.91M
YoY Change -479.54% -3.69% -405.46%
FREE CASH FLOW
Cash From Operating Activities $24.17M -$6.683M -$28.69M
Capital Expenditures $106.0K $72.00K $248.0K
Free Cash Flow $24.07M -$6.755M -$28.94M
YoY Change -477.11% -0.53% 58.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
100000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
100000
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.09
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.14
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12126573
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11538668
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001472012
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12128843
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12110373
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
500000
CY2022Q1 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesAndOtherLiabilities
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-39580
CY2022 dei Entity Registrant Name
EntityRegistrantName
IMMUNOME, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0694340
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
665 Stockton Drive
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Exton
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19341
CY2022 dei City Area Code
CityAreaCode
610
CY2022 dei Local Phone Number
LocalPhoneNumber
321-3700
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 Par Value
CY2022 dei Trading Symbol
TradingSymbol
IMNM
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
34100000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12215018
CY2022 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Firm
AuditorFirmId
34
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2022 dei Auditor Location
AuditorLocation
Philadelphia, Pennsylvania
CY2021 dei Auditor Name
AuditorName
Deloitte & Touche LLP
CY2021 dei Auditor Location
AuditorLocation
Philadelphia, Pennsylvania
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20323000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49229000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2326000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7409000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
22649000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
56638000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
681000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
855000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
284000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2022Q4 us-gaap Deferred Costs
DeferredCosts
332000
CY2021Q4 us-gaap Deferred Costs
DeferredCosts
332000
CY2022Q4 us-gaap Assets
Assets
24046000
CY2021Q4 us-gaap Assets
Assets
57925000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2400000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3077000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
4931000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6651000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7331000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9728000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
62000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
12000
CY2022Q4 us-gaap Liabilities
Liabilities
7393000
CY2021Q4 us-gaap Liabilities
Liabilities
9740000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12128843
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12110373
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
132653000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
127289000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116001000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79105000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
16653000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
48185000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24046000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57925000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23272000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14110000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13629000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11094000
CY2022 us-gaap Operating Expenses
OperatingExpenses
36901000
CY2021 us-gaap Operating Expenses
OperatingExpenses
25204000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-36901000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-25204000
CY2021 us-gaap Other Income
OtherIncome
503000
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5000
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-10000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
493000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-36896000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-24711000
CY2022 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
622000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37518000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24711000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.09
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.14
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12126573
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11538668
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
41345000
CY2021 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
559000
CY2021 imnm Stock Issued During Period Value Common Stock And Warrants
StockIssuedDuringPeriodValueCommonStockAndWarrants
26666000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3448000
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1338000
CY2021 imnm Stock Issued During Period Value Stock Options Exercised And Vesting Of Restricted Stock
StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfRestrictedStock
99000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-24711000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
48185000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5332000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-36896000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
16653000
CY2022 us-gaap Profit Loss
ProfitLoss
-36896000
CY2021 us-gaap Profit Loss
ProfitLoss
-24711000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
422000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
755000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
209000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
5332000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
3448000
CY2021 imnm Deferred Rent
DeferredRent
4000
CY2021 imnm Forgiveness Of Ppp Loan
ForgivenessOfPppLoan
-500000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5071000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4281000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-677000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1780000
CY2022 imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-1922000
CY2021 imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
5279000
CY2022 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-229000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28690000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18226000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
248000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
79000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-248000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-79000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
99000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1338000
CY2021 imnm Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
27225000
CY2021 imnm Payments Of Common Stock And Warrants Issuance Costs
PaymentsOfCommonStockAndWarrantsIssuanceCosts
559000
CY2021 imnm Repayments Of Equipment Loan
RepaymentsOfEquipmentLoan
113000
CY2021 imnm Payment Of Offering Costs
PaymentOfOfferingCosts
222000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27768000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-28906000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9463000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49329000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39866000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20423000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49329000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
14000
CY2022 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
492000
CY2021 imnm Offering Cost In Accounts Payable
OfferingCostInAccountsPayable
110000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-36900000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-24700000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116000000.0
CY2022 imnm Proceeds From Issuance Of Equity And Debt
ProceedsFromIssuanceOfEquityAndDebt
125100000
CY2022 imnm Reimbursement Received
ReimbursementReceived
17600000
CY2021Q4 imnm Shares Authorized For Issuance Amount
SharesAuthorizedForIssuanceAmount
200000000.0
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the expected volatility used to estimate fair value of stock options and accrued research and development expenses. Estimates and assumptions are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from these estimates.</p>
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20323000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49229000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20423000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49329000
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
300000
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
300000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3822517
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3308868
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
500000
CY2022Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
600000
CY2022Q3 imnm Deemed Dividends Stockholder S Equity Statement Impact
DeemedDividendsStockholderSEquityStatementImpact
0
CY2022Q4 imnm Prepaid Subscriptions Prepaid Service Contracts And Short Term Deposits
PrepaidSubscriptionsPrepaidServiceContractsAndShortTermDeposits
876000
CY2021Q4 imnm Prepaid Subscriptions Prepaid Service Contracts And Short Term Deposits
PrepaidSubscriptionsPrepaidServiceContractsAndShortTermDeposits
492000
CY2022Q4 imnm Employee Retention Credit Receivable
EmployeeRetentionCreditReceivable
847000
CY2022Q4 imnm Research And Development Expense Advance Payments
ResearchAndDevelopmentExpenseAdvancePayments
445000
CY2021Q4 imnm Research And Development Expense Advance Payments
ResearchAndDevelopmentExpenseAdvancePayments
586000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
158000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2019000
CY2021Q4 imnm Reimbursement Receivable Current
ReimbursementReceivableCurrent
2674000
CY2021Q4 imnm Unbilled Reimbursement Receivable Current
UnbilledReimbursementReceivableCurrent
1638000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2326000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7409000
CY2021 imnm Collaborative Agreement Milestone Payments Made
CollaborativeAgreementMilestonePaymentsMade
0
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
4132000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
3884000
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
3451000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
3029000
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
681000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
855000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
400000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
800000
CY2021Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
0
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
0
CY2020Q1 imnm Refundable Employee Retention Credit
RefundableEmployeeRetentionCredit
800000
CY2022 imnm Contra Research And Development Expense
ContraResearchAndDevelopmentExpense
600000
CY2022 imnm Contra General And Administrative Expense
ContraGeneralAndAdministrativeExpense
200000
CY2021 imnm Contra Expenses
ContraExpenses
0
CY2022Q4 imnm Employee Retention Credit Receivable
EmployeeRetentionCreditReceivable
800000
CY2021Q4 imnm Employee Retention Credit Receivable
EmployeeRetentionCreditReceivable
0
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
18470
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.76
CY2022 imnm Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm
P6Y7M13D
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2261000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2840000
CY2022Q4 imnm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1874000
CY2021Q4 imnm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1246000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
481000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
227000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
293000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
317000
CY2022Q4 imnm Deferred Research Obligations Liabilities Current
DeferredResearchObligationsLiabilitiesCurrent
22000
CY2021Q4 imnm Deferred Research Obligations Liabilities Current
DeferredResearchObligationsLiabilitiesCurrent
2021000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
4931000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6651000
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
CY2022Q4 imnm Collaborative Arrangements Product Development And Regulatory Approval Milestone Payments Payable
CollaborativeArrangementsProductDevelopmentAndRegulatoryApprovalMilestonePaymentsPayable
2600000
CY2022Q4 imnm Collaborative Arrangements Commercial Milestone Payments Payable
CollaborativeArrangementsCommercialMilestonePaymentsPayable
1500000
CY2022 imnm Collaborative Agreement Milestone Payments Made
CollaborativeAgreementMilestonePaymentsMade
100000
CY2022 imnm Common Stock Voting Right
CommonStockVotingRight
1
CY2021Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
14115
CY2021Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
15.94
CY2022Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
600000
CY2022Q3 imnm Deemed Dividends Stockholder S Equity Statement Impact
DeemedDividendsStockholderSEquityStatementImpact
0
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2519405
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.60
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5332000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3448000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
9200000
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.856
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.830
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.027
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.010
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022Q4 imnm Fair Value Of Common Stock
FairValueOfCommonStock
3.63
CY2021Q4 imnm Fair Value Of Common Stock
FairValueOfCommonStock
23.04
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2005756
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.26
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
563900
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.63
CY2022 imnm Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm
P9Y2M8D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
24990
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.97
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
6791
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
17.54
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1239114
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.86
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y3M18D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.65
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
16.49
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
800000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
900000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.043
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.080
CY2022 imnm Effective Income Tax Rate Reconciliation State Tax Legislation Net Of Federal Benefit Percent
EffectiveIncomeTaxRateReconciliationStateTaxLegislationNetOfFederalBenefitPercent
-0.071
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.019
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.024
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.002
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.003
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.199
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.317
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
20523000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19925000
CY2022Q4 imnm Deferred Tax Assets Research And Development Intangibles
DeferredTaxAssetsResearchAndDevelopmentIntangibles
4839000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2878000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2157000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2016000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
886000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
383000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
331000
CY2022Q4 imnm Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
1000
CY2021Q4 imnm Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
1000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
30640000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23300000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
30609000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
23255000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
31000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
45000
CY2022Q4 imnm Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
31000
CY2021Q4 imnm Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
45000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7400000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7800000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
81000000.0
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
81400000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
64000000.0
CY2020 imnm Net Operating Loss Carryforwards Offset Percent Of Taxable Income Maximum Percentage
NetOperatingLossCarryforwardsOffsetPercentOfTaxableIncomeMaximumPercentage
0.80
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001558370-23-003964-index-headers.html Edgar Link pending
0001558370-23-003964-index.html Edgar Link pending
0001558370-23-003964.txt Edgar Link pending
0001558370-23-003964-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20221231.xsd Edgar Link pending
tmb-20221231x10k.htm Edgar Link pending
tmb-20221231x10k001.jpg Edgar Link pending
tmb-20221231xex10d10.htm Edgar Link pending
tmb-20221231xex10d12.htm Edgar Link pending
tmb-20221231xex10d12001.jpg Edgar Link pending
tmb-20221231xex10d20.htm Edgar Link pending
tmb-20221231xex10d21.htm Edgar Link pending
tmb-20221231xex10d24.htm Edgar Link pending
tmb-20221231xex10d29.htm Edgar Link pending
tmb-20221231xex10d30.htm Edgar Link pending
tmb-20221231xex10d31.htm Edgar Link pending
tmb-20221231xex10d31001.jpg Edgar Link pending
tmb-20221231xex10d32.htm Edgar Link pending
tmb-20221231xex10d33.htm Edgar Link pending
tmb-20221231xex10d34.htm Edgar Link pending
tmb-20221231xex10d34001.jpg Edgar Link pending
tmb-20221231xex23d1.htm Edgar Link pending
tmb-20221231xex23d2.htm Edgar Link pending
tmb-20221231xex31d1.htm Edgar Link pending
tmb-20221231xex31d2.htm Edgar Link pending
tmb-20221231xex32d1.htm Edgar Link pending
tmb-20221231xex32d2.htm Edgar Link pending
tmb-20221231xex4d6.htm Edgar Link pending
tmb-20221231_cal.xml Edgar Link unprocessable
tmb-20221231_def.xml Edgar Link unprocessable
tmb-20221231x10k_htm.xml Edgar Link completed
tmb-20221231_lab.xml Edgar Link unprocessable
tmb-20221231_pre.xml Edgar Link unprocessable